These findings suggest that breast cancer has an intrinsically chemoresistant cellular population, defined as CD44+/CD24-, and that anti-HER2 therapy could eradicate this population of cells or CSCs in HER2+ breast cancer. Here, ERBB2 is linked to breast cancer.